Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HUYGENS evolocumab OCT plaque study in NSTE-ACS
NL-OMON48805Phase 3Completed
- Sponsor
- Amgen
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS), hypercholesterolemia, dyslipidemia and 1 more comparing Evolocumab plus statin with Placebo plus statin (2 arms). Primary endpoint: Change in fibrous cap thickness. Started Nov 2018; status: completed.
02
Drugs
evolocumab
03
Conditions
acute coronary syndrome (ACS)hypercholesterolemiadyslipidemiacoronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON48805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48805.